Search

: Objectives The aim was to study the pharmacokinetic profile of artesunate and its metabolite dihydroartemisinin (DHA) in a pig model. : Methods Thirteen pigs received either intravenous (iv) or intramuscular (im) artesunate (60 mg), with the alternative preparation given 24 h later in an open crossover design. Five of them also received an additional intra-arterial (ia) artesunate dose (60 mg). The plasma concentrations of artesunate and DHA were determined by high-performance liquid chromatography with electrochemical detection. Population modelling was performed with NONMEM, using a two-compartment model. : Results Plasma concentration–time profiles were comparable to those observed in humans, with a rapid and biphasic decline for both artesunate and DHA. Following an iv bolus, artesunate had a median maximum plasma concentration (Cmax) of 13.8 µM [interquartile range (IQR), 10.4–22.1 µM], elimination half-life (t1/2) = 18 min (IQR, 16–22 min), total plasma clearance (CL) = 5.58 L/h/kg (IQR, 3.31–5.91 L/h/kg) and volume of distribution (Vd) = 1.85 L/kg (IQR, 1.27–3.20 L/kg). The median Cmax value for DHA was 3.30 µM (IQR, 2.08–5.95 µM), t1/2 = 26 min (IQR, 23–31 min), CL/Fm = 4.37 L/h/kg (IQR, 3.29–6.87 L/h/kg) and Vd/Fm = 2.56 L/kg (IQR, 1.93–4.49 L/kg). Artesunate and DHA pharmacokinetic parameters were similar after ia administration. Following im dosing, median artesunate Cmax was 4.81 µM (IQR, 3.74–5.40 µM), t1/2 = 18 min (IQR, 16–28 min), CL = 4.37 L/h/kg (IQR, 4.13–4.68 L/h/kg) and Vd = 2.07 L/kg (IQR, 1.83–2.79 L/kg); the bioavailability was 100%. For DHA, median Cmax was 1.43 µM (IQR, 1.00–1.92 µM), t1/2 = 27 min (IQR, 25–37 min), CL/Fm = 4.68 L/h/kg (IQR, 3.35–6.73 L/h/kg) and Vd/Fm = 3.31 L/kg (IQR, 2.89–4.27 L/kg). : Conclusions The pharmacokinetic properties of artesunate and DHA in pigs were similar to those reported in humans, suggesting that the swine model is suitable for determining the preclinical pharmacokinetics of artemisinin derivatives. [ABSTRACT FROM AUTHOR]